NeuroSense Therapeutics receives Nasdaq minimum bid price notification

NeuroSense Therapeutics ( NASDAQ: NRSN ) on Friday said it has received a notification letter from Nasdaq, notifying that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing. NRSN +1.12% after hours to $0.

9. Source: Press Release More on NeuroSense Therapeutics Seeking Alpha’s Quant Rating on NeuroSense Therapeutics Historical earnings data for NeuroSense Therapeutics Financial information for NeuroSense Therapeutics.